CRISPR Therapeutics (CRSP) to Release Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business’s revenue was up 71.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.43) earnings per share. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Down 1.4%

Shares of NASDAQ CRSP opened at $35.62 on Monday. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -8.15 and a beta of 1.88. The stock’s fifty day simple moving average is $38.15 and its 200 day simple moving average is $42.71. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88.

Insider Activity at CRISPR Therapeutics

In related news, Director John Greene bought 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The stock was bought at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares in the company, valued at approximately $313,950. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 in the last ninety days. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

CRSP has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Stifel Nicolaus reduced their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Royal Bank of Canada reduced their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 12th. The Goldman Sachs Group cut their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Truist Financial increased their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.